Data from the ECHELON-3 trial support the approval of the brentuximab vedotin combo in relapsed/refractory B-cell lymphoma.
Approval Alert | Brentuximab Vedotin Plus Lenalidomide/Rituximab in R/R LBCL
Advertisement
Advertisement
Trending on CancerNetwork
1
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
Early Treatment Support and Real-World Care Gaps
4
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
5